| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | VRNA | Ordinary Shares | Award | $0 | +200,000 | +1.4% | $0.000000 | 14,404,752 | 01 Feb 2025 | Direct | F1, F2 |
| transaction | VRNA | Ordinary Shares | Tax liability | $1,194,189 | -166,728 | -1.2% | $7.16 | 14,238,024 | 03 Feb 2025 | Direct | F1, F3, F4, F5 |
| Id | Content |
|---|---|
| F1 | Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. |
| F2 | Represents an award of Ordinary Shares upon vesting of Performance Restricted Share Units in connection with the Issuer's first commercial sale of ensifentrine. |
| F3 | Represents the number of Ordinary Shares withheld to satisfy the tax withholding obligation in connection with the vesting of certain previously reported Restricted Share Units. |
| F4 | The price reported represents the closing price of the Issuer's ADSs on the Nasdaq Stock Market LLC on January 31, 2025 divided by eight (8). |
| F5 | Consists of (i) 2,725,000 Ordinary Shares underlying Restricted Share Units, each of which represents a contingent right to receive one (1) Ordinary Share of the Issuer (which are represented by 340,625 ADSs); and (ii) 11,513,024 Ordinary Shares underlying 1,439,128 ADSs. |